$10.770
+0.051 (+0.47%)收盤時
RTSN 同業比較
In the context of the broader market, RTSN competes directly with industry leaders such as GNLX and LENZ. With a market capitalization of $84.87M, it holds a significant position in the sector. When comparing efficiency, RTSN's gross margin of N/A stands against GNLX's N/A and LENZ's 86.58%. Such benchmarking helps identify whether Retension Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.
Retension Pharmaceuticals, Inc. Common Stock 財務表現
Retension Pharmaceuticals has been experiencing negative net income, with Q2 2026 reporting -4,170,589 USD. The company has a current ratio of 5.61, indicating it can cover its current liabilities with its current assets, which stood at 16,127,376 USD in Q2 2026.
Financials
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。